{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"388.0","value":"86.45"},{"groupId":"OG001","lowerLimit":"106.0","upperLimit":"515.0","value":"159.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.8","upperLimit":"369.0","value":"130.00"},{"groupId":"OG001","lowerLimit":"105.0","upperLimit":"492.0","value":"262.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.7","upperLimit":"410.0","value":"149.00"},{"groupId":"OG001","lowerLimit":"139.0","upperLimit":"908.0","value":"247.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"165.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"265.0","value":"88.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.00"},{"comment":"Full range is not applicable as only a single participant was analyzed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 29, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.0","upperLimit":"177.0","value":"118.50"},{"groupId":"OG001","lowerLimit":"95.6","upperLimit":"229.0","value":"163.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.9","upperLimit":"161.0","value":"127.00"},{"groupId":"OG001","lowerLimit":"50.3","upperLimit":"185.0","value":"83.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.0","upperLimit":"395.0","value":"108.00"},{"groupId":"OG001","lowerLimit":"115.0","upperLimit":"183.0","value":"166.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.3","upperLimit":"95.7","value":"88.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"137.0","value":"81.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.5","upperLimit":"155.0","value":"111.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CYCLE 18 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"END OF TREATMENT (~143 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28; with Lenalidomide 25 mg (10 mg if Estimated Glomerular Filtration (eGFR) is 40-60 milliLitre (mL)/minute/1.73 square meter (m)\\^2) administered orally once daily (QD) from Day 1 to Day 21; and Dexamethasone 40 mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone"},{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.0 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution infused over 30- 60 minutes Q4W for cycle 1 and then Q8W for cycle 2 onwards on day 1 of 28-day cycle in Q4W and 56-day cycle in Q8W in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28; with Lenalidomide 25 mg (10 mg if Estimated Glomerular Filtration (eGFR) is 40-60 milliLitre (mL)/minute/1.73 square meter (m)\\^2) administered orally once daily (QD) from Day 1 to Day 21; and Dexamethasone 40 mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Predose, end of infusion (EOI), and 2 hours postdose on Cycle 1 Day 1; anytime samples at Cycle 1 Day 4, 8, 29; Predose and EOI on Day 1 of Cycle 2, 4, 6, 9, 12; Predose on Cycle 18 Day 1; and end of treatment (~143 weeks)","title":"DE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"Picogram / millilitre (pg/mL)"}